GlassScriptPhysician profile
Christopher J Yamamoto
NPI 1164586004
$6,427.81
in general payments reported to CMS, 2019-2025
45 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $592 · 2021: $288 · 2022: $1,024 · 2023: $1,060 · 2024: $1,155 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,637.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $941.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $921.49 | 2019-2025 | |
| Abbvie INC. | $732.98 | 2019-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $422.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $385.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $329.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $274.35 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.06 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $200.39 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $157.09 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $156.06 | 2019-2023 | |
| Abbott Laboratories | $147.89 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $137.53 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $94.12 | 2023-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $83.24 | 2019-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Yamamoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.